News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Any Sanofi-Aventis (France) Deal For Genzyme Corporation May Take Time, At Limited Price
August 19, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Wall Street Journal -- NEW YORK (Dow Jones)--French drug maker Sanofi-Aventis SA's (SNY, SAN.FR) pursuit of Genzyme Corp. (GENZ) is more likely to be a drawn out engagement rather than a shotgun wedding, and there may be other suitors.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Mergers & acquisitions
Sanofi (France)
MORE ON THIS TOPIC
Mergers & acquisitions
Zenas Bets $2B+ in Autoimmune Agreement With Chinese Firm InnoCare
October 8, 2025
·
2 min read
·
Tristan Manalac
Layoff Tracker
Novo’s Cuts Leave Dozens of Manufacturing Workers Jobless
October 8, 2025
·
69 min read
·
BioSpace Editorial Staff
Podcast
Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa
October 8, 2025
·
1 min read
·
Heather McKenzie
IPOs
UPDATE: MapLight Seeks $227M IPO for Neuropsych Portfolio
October 7, 2025
·
3 min read
·
Tristan Manalac